UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) has been given an average rating of "Buy" by the six research firms that are covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $38.20.
Several equities research analysts recently issued reports on the company. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Monday, March 10th. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective for the company. Finally, HC Wainwright lowered their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th.
Check Out Our Latest Research Report on URGN
UroGen Pharma Price Performance
URGN stock traded up $0.17 during mid-day trading on Friday, reaching $11.70. 233,174 shares of the company traded hands, compared to its average volume of 370,836. The company has a fifty day moving average price of $10.47 and a 200-day moving average price of $11.60. UroGen Pharma has a 52-week low of $9.03 and a 52-week high of $20.70. The company has a market capitalization of $539.07 million, a P/E ratio of -3.71 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. As a group, analysts anticipate that UroGen Pharma will post -3.12 earnings per share for the current year.
Insider Activity
In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company's stock.
Hedge Funds Weigh In On UroGen Pharma
Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC increased its position in UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock valued at $759,000 after purchasing an additional 48,040 shares during the period. JPMorgan Chase & Co. increased its position in shares of UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after buying an additional 49,318 shares during the period. Geode Capital Management LLC raised its stake in UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock worth $5,787,000 after buying an additional 34,248 shares in the last quarter. Vestal Point Capital LP purchased a new stake in UroGen Pharma in the third quarter worth about $5,080,000. Finally, State Street Corp lifted its holdings in UroGen Pharma by 5.9% in the third quarter. State Street Corp now owns 769,583 shares of the company's stock worth $9,774,000 after buying an additional 42,907 shares during the period. 91.29% of the stock is owned by institutional investors.
UroGen Pharma Company Profile
(
Get Free ReportUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Articles
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
